Cetuximab in treatment of metastatic colorectal cancer: final survival analyses and extended RAS data from the NORDIC-VII study

Laetitia Dahan, Amine Sadok, Jean-Louis Formento, Jean François Seitz, Hervé Kovacic, Modulation of cellular redox state underlies antagonism between oxaliplatin and cetuximab in human colorectal cancer cell lines British Journal of Pharmacology. ,vol. 158, pp. 610- 620 ,(2009) , 10.1111/J.1476-5381.2009.00341.X

Sergej Skvortsov, Bettina Sarg, Herbert Lindner, Peter Lukas, Wolfgang Hilbe, Heinz Zwierzina, Ira Skvortsova, Cetuximab inhibits thymidylate synthase in colorectal cells expressing epidermal growth factor receptor. Proteomics Clinical Applications. ,vol. 2, pp. 908- 914 ,(2008) , 10.1002/PRCA.200780034

A Harstrick, A Gonzales, N Schleucher, U Vanhoefer, Kun Lu, JL Formento, G Milano, H Wilke, S Seeber, Y Rustum, Comparison between short or long exposure to 5-fluorouracil in human gastric and colon cancer cell lines: biochemical mechanism of resistance. Anti-Cancer Drugs. ,vol. 9, pp. 625- 634 ,(1998) , 10.1097/00001813-199808000-00008

Harith Rajagopalan, Alberto Bardelli, Christoph Lengauer, Kenneth W. Kinzler, Bert Vogelstein, Victor E. Velculescu, Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature. ,vol. 418, pp. 934- 934 ,(2002) , 10.1038/418934A

C. Bokemeyer, C.-H. Köhne, F. Ciardiello, H.-J. Lenz, V. Heinemann, U. Klinkhardt, F. Beier, K. Duecker, J.H. van Krieken, S. Tejpar, FOLFOX4 plus cetuximab treatment and RAS mutations in colorectal cancer European Journal of Cancer. ,vol. 51, pp. 1243- 1252 ,(2015) , 10.1016/J.EJCA.2015.04.007

Hwang-Phill Kim, Young-Kwang Yoon, Jin-Won Kim, Sae-Won Han, Hyung-Seok Hur, Jinah Park, Ju-Hee Lee, Do-Youn Oh, Seock-Ah Im, Yung-Jue Bang, Tae-You Kim, Lapatinib, a Dual EGFR and HER2 Tyrosine Kinase Inhibitor, Downregulates Thymidylate Synthase by Inhibiting the Nuclear Translocation of EGFR and HER2 PLoS ONE. ,vol. 4, pp. e5933- ,(2009) , 10.1371/JOURNAL.PONE.0005933

Halfdan Sørbye, Bengt Glimelius, Åke Berglund, Tone Fokstuen, Kjell Magne Tveit, Morten Brændengen, Dagfinn Øgreid, Olav Dahl, Multicenter Phase II Study of Nordic Fluorouracil and Folinic Acid Bolus Schedule Combined With Oxaliplatin As First-Line Treatment of Metastatic Colorectal Cancer Journal of Clinical Oncology. ,vol. 22, pp. 31- 38 ,(2004) , 10.1200/JCO.2004.05.188

Jean-Yves Douillard, Kelly S Oliner, Salvatore Siena, Josep Tabernero, Ronald Burkes, Mario Barugel, Yves Humblet, Gyorgy Bodoky, David Cunningham, Jacek Jassem, Fernando Rivera, Ilona Kocákova, Paul Ruff, Maria Błasińska-Morawiec, Martin Šmakal, Jean Luc Canon, Mark Rother, Richard Williams, Alan Rong, Jeffrey Wiezorek, Roger Sidhu, Scott D Patterson, None, Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer The New England Journal of Medicine. ,vol. 369, pp. 1023- 1034 ,(2013) , 10.1056/NEJMOA1305275

Eric Van Cutsem, Claus-Henning Köhne, Erika Hitre, Jerzy Zaluski, Chung-Rong Chang Chien, Anatoly Makhson, Geert D'Haens, Tamás Pintér, Robert Lim, György Bodoky, Jae Kyung Roh, Gunnar Folprecht, Paul Ruff, Christopher Stroh, Sabine Tejpar, Michael Schlichting, Johannes Nippgen, Philippe Rougier, Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. The New England Journal of Medicine. ,vol. 360, pp. 1408- 1417 ,(2009) , 10.1056/NEJMOA0805019

Jean-Yves Douillard, Salvatore Siena, James Cassidy, Josep Tabernero, Ronald Burkes, Mario Barugel, Yves Humblet, György Bodoky, David Cunningham, Jacek Jassem, Fernando Rivera, Ilona Kocákova, Paul Ruff, Maria Błasińska-Morawiec, Martin Šmakal, Jean-Luc Canon, Mark Rother, Kelly S Oliner, Michael Wolf, Jennifer Gansert, None, Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study Journal of Clinical Oncology. ,vol. 28, pp. 4697- 4705 ,(2010) , 10.1200/JCO.2009.27.4860